Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Food allergy tied to lower risk for SARS-CoV-2 infection
Jun 09, 2022
Asthma does not raise the risk for infection or household transmission.
Most neurologic symptoms persist for COVID-19 long haulers
Jun 02, 2022
SARS-CoV-2 vaccination appears to have no positive or negative impact on cognitive function or fatigue.
Vaccination cuts risk of severe COVID-19 in patients on dialysis
Jun 01, 2022
There was a reduction in risk of admission and deaths with prior two-dose vaccination versus no vaccination.
Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Proportion of asymptomatic SARS-CoV-2 infections unclear
May 27, 2022
Most SARS-CoV-2 infections are not asymptomatic; those with asymptomatic infections are less infectious.
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
No specific causes of symptoms of postacute sequelae of SARS-CoV-2 infection were identified.
Antibody levels after COVID-19 vaccination inversely linked to body weight
May 23, 2022
An inverse correlation was sustained for up to six months following two doses of BNT162b2 (Pfizer–BioNTech) in a small cohort of healthy young and middle-aged adults.
Loss of smell, taste less likely with newer COVID-19 variants
May 18, 2022
A lower risk for developing chemosensory loss was observed with the alpha, delta and omicron variants.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.